Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Scandinavian Journal of Infectious Diseases|July 24, 2013
HIV-associated lung cancer: survival in an unselected cohortChristian Hoffmann, Fabienne Kohrs, Michael Sabranski, et al.Vaccine|October 23, 2013
Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled studyThomas Harrer, Andreas Plettenberg, Keikawus Arastéh, et al.Leukemia & Lymphoma|October 27, 2006
AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveChristian Hoffmann, Eva Wolf, Christoph Wyen, et al.British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.AIDS (London, England)|September 22, 2006
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfectionGuenther Schmutz, Mark Nelson, Thomas Lutz, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 27, 2010
Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification testsJoachim Glaubitz, Dorothea Sizmann, Christian O Simon, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2010
Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognitionSandra M Mueller, Bernd M Spriewald, Silke Bergmann, et al.The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.The Journal of Antimicrobial Chemotherapy|July 1, 2011
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensChristoph Wyen, Heidy Hendra, Marco Siccardi, et al.The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.Pageof 4